Emergency Med

Your Article Summary

See Latest Articles

Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule
Drugs of Today, 10/19/09

Tzschentke TM et al. – Tapentadol exerts its analgesic effects through mu opioid receptor agonism and noradrenaline reuptake inhibition in the central nervous system. Preclinical studies demonstrated that tapentadol is effective in a broad range of pain models, including nociceptive, inflammatory, visceral, mono– and polyneuropathic models. Moreover, clinical studies showed that tapentadol effectively relieves moderate to severe pain in various pain care settings. In addition, it was reported to be associated with significantly fewer treatment discontinuations due to a significantly lower incidence of gastrointestinal–related adverse events compared with equivalent doses of oxycodone. The combination of these reduced treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing patient compliance with their treatment regimen.

Today in Pain Management...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/19/09

Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09

See All of Pain Management